Pharming Group N.V. Logo

Pharming Group N.V.

PHGUF

(0.5)
Stock Price

0,75 USD

-3.69% ROA

-6.1% ROE

-39.78x PER

Market Cap.

512.157.270,00 USD

50.22% DER

0% Yield

-4.62% NPM

Pharming Group N.V. Stock Analysis

Pharming Group N.V. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Pharming Group N.V. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock maintains a fair debt to equity ratio (78%), indicating a reasonable balance between the money it owes and the ownership it possesses.

2 Assets Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

3 ROE

Negative ROE (-10.83%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-6.02%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 PBV

The stock's elevated P/BV ratio (3.56x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-6) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Pharming Group N.V. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Pharming Group N.V. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Pharming Group N.V. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Pharming Group N.V. Revenue
Year Revenue Growth
2005 479.681
2006 194.010 -147.25%
2007 1.006.021 80.72%
2008 924.353 -8.84%
2009 479.970 -92.59%
2010 762.069 37.02%
2011 3.886.980 80.39%
2012 14.035.760 72.31%
2013 9.450.689 -48.52%
2014 25.762.439 63.32%
2015 11.838.278 -117.62%
2016 16.693.660 29.09%
2017 107.517.335 84.47%
2018 154.575.611 30.44%
2019 189.333.721 18.36%
2020 228.394.666 17.1%
2021 189.853.037 -20.3%
2022 205.622.000 7.67%
2023 266.644.000 22.89%
2023 245.316.000 -8.69%
2024 294.908.388 16.82%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Pharming Group N.V. Research and Development Expenses
Year Research and Development Expenses Growth
2005 10.566.024
2006 0 0%
2007 27.830.346 100%
2008 30.744.494 9.48%
2009 0 0%
2010 24.347.652 100%
2011 17.924.956 -35.83%
2012 25.882.773 30.75%
2013 14.129.083 -83.19%
2014 14.182.353 0.38%
2015 15.503.028 8.52%
2016 16.183.585 4.21%
2017 22.382.849 27.7%
2018 33.038.206 32.25%
2019 31.777.040 -3.97%
2020 41.464.134 23.36%
2021 67.178.053 38.28%
2022 52.531.000 -27.88%
2023 83.012.000 36.72%
2023 68.914.000 -20.46%
2024 85.965.196 19.83%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Pharming Group N.V. General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 0
2006 0 0%
2007 4.117.398 100%
2008 4.595.316 10.4%
2009 0 0%
2010 4.267.854 100%
2011 5.574.492 23.44%
2012 4.270.373 -30.54%
2013 3.477.036 -22.82%
2014 4.042.025 13.98%
2015 4.093.324 1.25%
2016 4.881.999 16.15%
2017 7.167.022 31.88%
2018 7.327.842 2.19%
2019 21.185.814 65.41%
2020 14.418.724 -46.93%
2021 35.296.981 59.15%
2022 46.016.000 23.29%
2023 43.544.000 -5.68%
2023 80.684.000 46.03%
2024 62.480.000 -29.14%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Pharming Group N.V. EBITDA
Year EBITDA Growth
2005 -19.113.833
2006 -23.799.971 19.69%
2007 -48.227.798 50.65%
2008 -17.424.896 -176.78%
2009 479.970 3730.41%
2010 -33.912.754 101.42%
2011 -23.933.640 -41.69%
2012 -25.966.091 7.83%
2013 -15.708.802 -65.3%
2014 3.717.350 522.58%
2015 -13.304.397 127.94%
2016 -13.946.616 4.6%
2017 -3.767.066 -270.22%
2018 50.982.612 107.39%
2019 75.414.463 32.4%
2020 92.114.779 18.13%
2021 46.560.313 -97.84%
2022 32.606.000 -42.8%
2023 31.444.000 -3.7%
2023 -2.838.000 1207.96%
2024 -16.983.764 83.29%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Pharming Group N.V. Gross Profit
Year Gross Profit Growth
2005 -5.694.591
2006 -23.799.971 76.07%
2007 -35.897.473 33.7%
2008 924.353 3983.52%
2009 479.970 -92.59%
2010 639.713 24.97%
2011 -688.225 192.95%
2012 8.392.626 108.2%
2013 7.915.160 -6.03%
2014 21.595.165 63.35%
2015 6.590.427 -227.67%
2016 11.768.542 44%
2017 92.587.038 87.29%
2018 129.203.843 28.34%
2019 165.412.447 21.89%
2020 203.056.430 18.54%
2021 169.670.071 -19.68%
2022 188.060.000 9.78%
2023 233.464.000 19.45%
2023 220.104.000 -6.07%
2024 263.069.428 16.33%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Pharming Group N.V. Net Profit
Year Net Profit Growth
2005 -21.152.183
2006 0 0%
2007 -31.552.627 100%
2008 -36.479.940 13.51%
2009 0 0%
2010 -66.784.147 100%
2011 -22.168.362 -201.26%
2012 -31.863.147 30.43%
2013 -20.795.935 -53.22%
2014 -7.012.744 -196.54%
2015 -10.886.012 35.58%
2016 -18.442.640 40.97%
2017 -91.473.715 79.84%
2018 28.589.567 419.95%
2019 40.557.000 29.51%
2020 37.746.000 -7.45%
2021 15.996.000 -135.97%
2022 13.674.000 -16.98%
2023 13.856.000 1.31%
2023 -10.548.000 231.36%
2024 -4.775.844 -120.86%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Pharming Group N.V. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 -3
2006 0 0%
2007 -3 100%
2008 -4 0%
2009 0 0%
2010 -2 100%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Pharming Group N.V. Free Cashflow
Year Free Cashflow Growth
2005 -16.277.197
2006 -29.576.740 44.97%
2007 -32.665.082 9.45%
2008 -1.133.168 -2782.63%
2009 -435.555 -160.17%
2010 -1.208.937 63.97%
2011 -21.942.842 94.49%
2012 -14.394.160 -52.44%
2013 -11.480.571 -25.38%
2014 -3.128.800 -266.93%
2015 0 0%
2016 -12.113.500 100%
2017 38.592.028 131.39%
2018 42.025.851 8.17%
2019 49.111.702 14.43%
2020 74.508.018 34.09%
2021 20.168.247 -269.43%
2022 20.920.000 3.59%
2023 -18.766.000 211.48%
2023 3.380.000 655.21%
2024 -13.319.428 125.38%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Pharming Group N.V. Operating Cashflow
Year Operating Cashflow Growth
2005 -15.259.798
2006 -25.418.047 39.96%
2007 -31.686.763 19.78%
2008 0 0%
2009 0 0%
2010 0 0%
2011 -21.942.842 100%
2012 -13.582.141 -61.56%
2013 -11.451.573 -18.61%
2014 -3.128.800 -266.01%
2015 0 0%
2016 -10.521.223 100%
2017 45.844.230 122.95%
2018 46.337.222 1.06%
2019 74.555.291 37.85%
2020 90.977.073 18.05%
2021 36.125.767 -151.83%
2022 22.897.000 -57.78%
2023 -17.302.000 232.34%
2023 3.527.000 590.56%
2024 -13.107.028 126.91%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Pharming Group N.V. Capital Expenditure
Year Capital Expenditure Growth
2005 1.017.399
2006 4.158.693 75.54%
2007 978.320 -325.09%
2008 1.133.168 13.67%
2009 435.555 -160.17%
2010 1.208.937 63.97%
2011 0 0%
2012 812.019 100%
2013 28.998 -2700.26%
2014 0 0%
2015 0 0%
2016 1.592.276 100%
2017 7.252.201 78.04%
2018 4.311.370 -68.21%
2019 25.443.588 83.06%
2020 16.469.054 -54.49%
2021 15.957.519 -3.21%
2022 1.977.000 -707.16%
2023 1.464.000 -35.04%
2023 147.000 -895.92%
2024 212.400 30.79%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Pharming Group N.V. Equity
Year Equity Growth
2005 34.038.445
2006 65.782.839 48.26%
2007 0 0%
2008 17.447.169 100%
2009 19.074.158 8.53%
2010 13.432.636 -42%
2011 -1.539.758 972.39%
2012 -10.119.819 84.78%
2013 6.918.169 246.28%
2014 36.289.459 80.94%
2015 26.063.236 -39.24%
2016 28.887.089 9.78%
2017 19.327.206 -49.46%
2018 0 0%
2019 117.258.490 100%
2020 183.726.507 36.18%
2021 192.716.423 4.66%
2022 204.638.000 5.83%
2023 218.781.000 6.46%
2023 209.942.000 -4.21%
2024 209.722.647 -0.1%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Pharming Group N.V. Assets
Year Assets Growth
2005 40.964.811
2006 104.368.541 60.75%
2007 0 0%
2008 112.392.460 100%
2009 80.066.192 -40.37%
2010 49.591.701 -61.45%
2011 32.005.702 -54.95%
2012 22.276.298 -43.68%
2013 43.370.432 48.64%
2014 67.753.781 35.99%
2015 63.058.404 -7.45%
2016 133.337.890 52.71%
2017 199.378.554 33.12%
2018 0 0%
2019 255.634.465 100%
2020 419.115.910 39.01%
2021 396.902.244 -5.6%
2022 425.797.000 6.79%
2023 462.854.000 8.01%
2023 436.467.000 -6.05%
2024 415.683.507 -5%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Pharming Group N.V. Liabilities
Year Liabilities Growth
2005 6.926.365
2006 38.585.701 82.05%
2007 80.961.406 52.34%
2008 94.945.290 14.73%
2009 60.992.033 -55.67%
2010 36.159.063 -68.68%
2011 33.545.460 -7.79%
2012 32.396.117 -3.55%
2013 36.452.263 11.13%
2014 31.464.322 -15.85%
2015 36.995.167 14.95%
2016 104.450.801 64.58%
2017 180.051.347 41.99%
2018 0 0%
2019 138.375.974 100%
2020 235.389.402 41.21%
2021 204.185.820 -15.28%
2022 221.159.000 7.67%
2023 244.073.000 9.39%
2023 226.525.000 -7.75%
2024 205.960.860 -9.98%

Pharming Group N.V. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.41
Net Income per Share
-0.02
Price to Earning Ratio
-39.78x
Price To Sales Ratio
1.84x
POCF Ratio
-75.37
PFCF Ratio
-67.64
Price to Book Ratio
2.44
EV to Sales
2.14
EV Over EBITDA
455.98
EV to Operating CashFlow
-88.01
EV to FreeCashFlow
-78.99
Earnings Yield
-0.03
FreeCashFlow Yield
-0.01
Market Cap
0,51 Bil.
Enterprise Value
0,60 Bil.
Graham Number
0.36
Graham NetNet
0.03

Income Statement Metrics

Net Income per Share
-0.02
Income Quality
0.52
ROE
-0.06
Return On Assets
-0.03
Return On Capital Employed
-0.05
Net Income per EBT
0.85
EBT Per Ebit
0.84
Ebit per Revenue
-0.06
Effective Tax Rate
0.16

Margins

Sales, General, & Administrative to Revenue
0.32
Research & Developement to Revenue
0.26
Stock Based Compensation to Revenue
0.04
Gross Profit Margin
0.86
Operating Profit Margin
-0.06
Pretax Profit Margin
-0.05
Net Profit Margin
-0.05

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
-0.11
Capex to Revenue
0
Capex to Depreciation
0.05
Return on Invested Capital
-0.05
Return on Tangible Assets
-0.04
Days Sales Outstanding
66.84
Days Payables Outstanding
671.6
Days of Inventory on Hand
544.8
Receivables Turnover
5.46
Payables Turnover
0.54
Inventory Turnover
0.67
Capex per Share
0

Balance Sheet

Cash per Share
0,24
Book Value per Share
0,31
Tangible Book Value per Share
0.21
Shareholders Equity per Share
0.31
Interest Debt per Share
0.16
Debt to Equity
0.5
Debt to Assets
0.25
Net Debt to EBITDA
65.51
Current Ratio
3.39
Tangible Asset Value
0,14 Bil.
Net Current Asset Value
0,06 Bil.
Invested Capital
287860844
Working Capital
0,19 Bil.
Intangibles to Total Assets
0.16
Average Receivables
0,04 Bil.
Average Payables
0,07 Bil.
Average Inventory
57493231
Debt to Market Cap
0.21

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Pharming Group N.V. Dividends
Year Dividends Growth

Pharming Group N.V. Profile

About Pharming Group N.V.

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

CEO
Dr. Sijmen de Vries M.B.A., M
Employee
382
Address
Darwinweg 24
Leiden, 2333 CR

Pharming Group N.V. Executives & BODs

Pharming Group N.V. Executives & BODs
# Name Age
1 Mr. Stephen Toor
Chief Commercial Officer & GM Americas
70
2 Mr. Jeroen Wakkerman
Chief Financial Officer
70
3 Mr. Ruud Van Outersterp
Chief Ethics & Compliance Officer
70
4 Dr. Anurag Relan M.D., MPH
Chief Medical Officer
70
5 Dr. Alexander Breidenbach M.B.A.
Chief Business Officer
70
6 Dr. Sijmen de Vries M.B.A., M.D.
President, Chief Executive Officer & Executive Director
70
7 Ms. Mireille Sanders M.Sc.
Chief Operations Officer
70
8 Dr. Bruno M. L. Giannetti
Consultant
70
9 Susanne Embleton
Investor Relations Manager
70

Pharming Group N.V. Competitors